Using transgenic mouse models of thyroid cancer, Roelli and colleagues [24] showed that double mutants with Braf V600E and Pik3ca H1047R mutations had paradoxically increased ERK signaling when treated with BRAF inhibitors compared to single mutant mice with Braf V600E mutation alone. The gene discussed is BRAF; the disease is thyroid cancer.